Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.81 |
| ▸ | NPC1 | O15118 | 9/20 | 0.81 |
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | PKM | P14618 | 2/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23898944 | 1.00 | RAB9A (0.81) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL19601411 | 1.00 | RAB9A (0.81) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL16436156 | 1.00 | RAB9A (0.81) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL682875 | 1.00 | RAB9A (0.81) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL23805541 | 0.95 | NPC1 (0.73) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL1353478 | 0.90 | POLB (1.00) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL137276 | 0.90 | POLB (1.00) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL30319980 | 0.90 | POLB (1.00) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL2128727 | 0.90 | POLB (1.00) | RAB9ANPC1POLBMEN1LMNA | |
| SCHEMBL9681496 | 0.90 | POLB (1.00) | RAB9ANPC1POLBMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| JP-2011526912-A | — | — | 2011-10-20 | — | — | JP | claimed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | claimed |
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| CN-110520412-A | Compounds for the treatment of tuberculosis | UNIV NANYANG TECH | 2019-11-29 | — | — | CN | disclosed |
| CN-105884699-B | 4- substituted aniline quinazoline derivative and its preparation method and application | 中国药科大学 | 2019-05-07 | — | — | CN | disclosed |
| CN-107459480-A | A kind of substituted bisarylurea histon deacetylase (HDAC) inhibitor | 镇江斯格派医疗器械有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-9676935-B2 | Polyoxymethylene resin composition | HYUNDAI MOTOR COMPANY (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| CN-101952287-A | Kinases inhibitor and application thereof | MERCK SERONO SA | 2011-01-19 | — | — | CN | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-4230710-A | Amide derivatives of 2-substituted anilino-hexahydrobenzo[a]quinolizines, and methods of treating hypertension employing them | MILES LABORATORIES, INC. (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | RAB9A 2275/4885NPC1 1978/4885POLB 435/4885 |
| US-11078165-B2 | Compounds for treating tuberculosis | ATP5ME, ATP5MG, ATP5F1D | RAB9A 2809/4885NPC1 1580/4885POLB 327/4885 |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | ATP5ME, ATP5MG, ATP5F1D | RAB9A 2809/4885NPC1 1580/4885POLB 327/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | RAB9A 1390/4885NPC1 3403/4885POLB 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.